Related Experiment Video

Updated: Jun 21, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

When statin therapy stops: implications for the patient

Stella S Daskalopoulou1

  • 1Division of Internal Medicine, Department of Medicine, McGill University, McGill University Health Centre, Montreal, Québec, Canada. stella.daskalopoulou@mcgill.ca

Current Opinion in Cardiology
|July 4, 2009
PubMed

Insights

Discontinuing statin therapy, especially after heart attack or stroke, leads to worse cardiovascular outcomes and higher mortality. Patients should adhere to statin prescriptions unless medically contraindicated.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Statins are crucial for reducing cardiovascular events and mortality.
  • High rates of statin discontinuation persist in clinical practice, impacting patient adherence.
  • Recent evidence highlights the negative consequences of stopping statin therapy.

Purpose of the Study:

  • To review recent findings on the implications of statin discontinuation.
  • To emphasize the adverse effects associated with stopping statin medication.

Main Methods:

  • Review of recent studies and clinical data on statin use and discontinuation.
  • Analysis of cardiovascular outcomes and mortality rates in patients who discontinued statins versus those who continued or never used them.

Main Results:

  • Statin therapy significantly reduces inflammatory markers, cardiovascular events, and mortality.
  • Statin discontinuation, particularly post-acute events, is linked to poorer cardiovascular outcomes and increased all-cause mortality.
  • Outcomes for statin discontinuers were worse than for those never prescribed statins, potentially due to a biological rebound effect.

Conclusions:

  • Statin therapy provides significant patient benefits and should be prescribed per guidelines.
  • Statin discontinuation is associated with harmful outcomes and should be avoided, especially after acute vascular events.
  • Clinicians must counsel patients on statin adherence to prevent adverse cardiovascular events.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...